Close Menu

NEW YORK – Agilent Technologies announced on Monday it has received approval from the US Food and Drug Administration for its PD-L1 IHC 28-8 pharmDx as a companion diagnostic for expanded use in non-small cell lung cancer (NSCLC).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.